{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:37:47Z","timestamp":1780439867371,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00105-024-05410-y","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T07:02:18Z","timestamp":1725346938000},"page":"823-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Handlungsempfehlungen bei oraler Candidose unter Biologikatherapie bei Psoriasis\u00a0\u2013 Ergebnisse eines Expertenmeetings","Recommendations for the management of oral candidiasis during treatment with biologicals\u2014results from an expert meeting of dermatologists"],"prefix":"10.1007","volume":"75","author":[{"given":"Katharina","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khusru","family":"Asadullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"5410_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong\u00a0AW, Blauvelt\u00a0A, Mrowietz\u00a0U et\u00a0al (2022) A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatol Ther (Heidelb) 12:787\u2013800","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5410_CR2","unstructured":"Bimzelx Fachinformation. November 2023."},{"key":"5410_CR3","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson\u00a0L, Van Den Reek\u00a0J, Bruno\u00a0M et\u00a0al (2022) Risk of candidiasis associated with interleukin-17\u00a0inhibitors: A\u00a0real-world observational study of multiple independent sources. Lancet Reg Health Eur 13:100266","journal-title":"Lancet Reg Health Eur"},{"key":"5410_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/myc.13399","volume":"65","author":"K Elsner","year":"2022","unstructured":"Elsner\u00a0K, Holstein\u00a0J, Hilke\u00a0FJ et\u00a0al (2022) Prevalence of Candida species in Psoriasis. Mycoses 65:247\u2013254","journal-title":"Mycoses"},{"key":"5410_CR5","volume-title":"S1\u00a0Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie (PEG)","author":"AH Groll","year":"2020","unstructured":"Groll\u00a0AH, Buchheidt\u00a0D, Heinz\u00a0W et\u00a0al (2020) S1\u00a0Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie (PEG)"},{"issue":"1","key":"5410_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/myc.12292","volume":"58","author":"W Mendling","year":"2015","unstructured":"Mendling\u00a0W, Brasch\u00a0J, Cornely\u00a0OA et\u00a0al (2015) Guideline: vulvovaginal candidosis (AWMF 015\/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 58(1):1\u201315","journal-title":"Mycoses"},{"key":"5410_CR7","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et\u00a0al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil\u00a01: Therapieziele und Therapieempfehlungen. Jddg: J Dtsch Dermatologischen Ges 19:934\u2013951","journal-title":"Jddg: J Dtsch Dermatologischen Ges"},{"key":"5410_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri3897","volume":"15","author":"MG Netea","year":"2015","unstructured":"Netea\u00a0MG, Joosten\u00a0LA, Van Der Meer\u00a0JW et\u00a0al (2015) Immune defence against Candida fungal infections. Nat Rev Immunol 15:630\u2013642","journal-title":"Nat Rev Immunol"},{"key":"5410_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi\u00a0R, Symmons\u00a0DP, Griffiths\u00a0CE et\u00a0al (2013) Global epidemiology of psoriasis: a\u00a0systematic review of incidence and prevalence. J\u00a0Invest Dermatol 133:377\u2013385","journal-title":"J Invest Dermatol"},{"key":"5410_CR10","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1177\/12034754221111111","volume":"26","author":"J Yeung","year":"2022","unstructured":"Yeung\u00a0J, Bunce\u00a0PE, Lynde\u00a0CW et\u00a0al (2022) Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. J\u00a0Cutan Med Surg 26:3s\u201323s","journal-title":"J Cutan Med Surg"},{"key":"5410_CR11","volume-title":"Mykosen","author":"HJ Tietz","year":"2023","unstructured":"Tietz\u00a0HJ (2023) Mykosen. OmniMed\u00ae Verlagsgesellschaft mbH. ISBN 978-3-931766-49\u20118."}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05410-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05410-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05410-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:04:13Z","timestamp":1727791453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05410-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5410"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05410-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"18 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Meier: AbbVie Deutschland GmbH & Co. KG, Amgen GmbH, Almirall Hermal GmbH, AstraZeneca, Biogen GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Lilly Deutschland GmbH, Janssen-Cilag GmbH, UCB Pharma GmbH, Leo Pharma, Novartis Pharma GmbH, Takeda Pharmaceutical. S.\u00a0Beissert: Advisory Board: AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Deutschland GmbH, AMGEN GmbH, Celgene GmbH, Galderma Laboratorium GmbH, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, MSD SHARP & DOHME GMBH, Menlo Therapeutics, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH, UCB Pharma GmbH; Speaker honorarium: Novartis Pharma GmbH, AbbVie Deutschland GmbH & Co. KG, MSD SHARP & DOHME GMBH, Pfizer Pharma GmbH, Janssen-Cilag GmbH, Galderma Laboratorium GmbH, Celgene GmbH, LA ROCHE-POSAY LABORATOIRE PHARMACEUTIQUE, Actelion Pharmaceuticals Deutschland GmbH, GlaxoSmithKline GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Sanofi-Aventis Deutschland GmbH, Almirall Hermal GmbH, Sandoz\/HEXAL AG, Incyte Biosciences Germany GmbH; Clinical Trials: Janssen-Cilag GmbH, AMGEN GmbH, AbbVie Deutschland GmbH & Co. KG, Celldex Therapeutics, Aristea Therapeutics, Celgene GmbH, Galderma Laboratorium GmbH, Kiniksa Pharmaceuticals, LEO Pharma GmbH, DICE Therapeutic Inc., Lilly Deutschland GmbH, Novartis Pharma GmbH, MSD SHARP & DOHME GMBH, Menlo Therapeutics, Numab Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH, UCB Pharma GmbH, F.\u00a0Hoffmann-La Roche Ltd, DS Biopharma. K.\u00a0Ghoreschi: erhielt Honorare f\u00fcr Vortr\u00e4ge oder Beratungen von folgenden Firmen: AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis Pharma, Pfizer und UCB Pharma. S.\u00a0Philipp: Vortrags\u2011\/Beraterhonorare, klinische Studien: AbbVie, Almirall, Amgen, Biogen, BMS GmbH, Boehringer-Ingelheim, Eli Lilly, GSK, Hexal, Janssen Cilag, Klinge Pharma, Leo Pharma, MSD, Novartis, Pfizer, UCB Pharma. B.\u00a0Schwarz: AbbVie, Almirall, Amgen , Biogen, Bristol-Meyers-Squibb, Dermapharm, Ferrer, Galderma, Incyte, Janssen, Leo Pharma, Lilly Pharma, Novartis, Pfizer, Regeneron, Sanofi, UCB in Form von Studien, Vortr\u00e4gen und\/oder Beratert\u00e4tigkeit. H.-J.\u00a0Tietz: f\u00fchrt Vortr\u00e4ge und Seminare durch, mit Unterst\u00fctzung von: Bayer, Pierre Fabre, ISDIN, EUROIMMUN, UCB, Janssen, AbbVie. K.\u00a0Asadullah: kooperierte und erhielt finanzielle Zuwendungen von den folgenden Firmen: AbbVie, Almirall, Antabio, Bayer, Celltrion, Bristol-Myers Squibb, Euroimmune, Emphasis, Emeriti Pharma, Galderma, Janssen, La Roche-Posay, LEO, L\u2019Or\u00e9al, Novartis, Parexel International, Pierre Fabre, Roxall, RG, Sanofi Genzyme, TFS Trial Form Support, UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}